Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the third quarter ended September 30, 2020, and provided a business update on recent corporate and clinical developments.
October 29, 2020
· 13 min read